Cancer immunotherapy depends heavily on the ability of T cells to recognize tumors, sustain an immune response, and continue attacking malignant cells. Yet even when treatment initially appears effective, that response may gradually weaken as T cells enter a state known as exhaustion.
Researchers at Memorial Sloan Kettering Cancer Center have now identified a potential way to slow this process. Their findings suggest that controlling signaling through MEK, a molecule involved in regulating T-cell activity and energy use, may help immune cells remain functional for longer.
The preclinical study, published in Immunity, provides a new perspective on why T cells become exhausted and how existing MEK inhibitors might eventually be used to strengthen several forms of cancer immunotherapy.
When a Promising Immune Response Begins to Fade
Checkpoint inhibitors work by releasing molecular brakes that normally restrain T-cell activity. For some patients, these medicines can produce meaningful and durable responses. For others, however, the initial benefit may be short-lived.
“A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades,” said Santosha Vardhana, MD, PhD, a physician-scientist at Memorial Sloan Kettering Cancer Center who treats patients with lymphoma.
T-cell exhaustion develops when immune cells are repeatedly exposed to tumor antigens, the cancer-associated proteins that the immune system recognizes as foreign. Over time, the cells lose their ability to maintain a strong antitumor response and can reach a terminally exhausted state in which immunotherapy is no longer able to reactivate them effectively.
The laboratory of Dr. Vardhana found that MEK plays an important role in driving this process. In animal and laboratory models, blocking MEK signaling allowed T cells to persist under the difficult conditions found within tumors.
The Hidden Energy Cost of Fighting Cancer
The findings build on earlier work from Dr. Vardhana’s laboratory showing that T-cell exhaustion is closely connected to cellular metabolism.
When T cells encounter cancer cells, they must produce large quantities of cytotoxic proteins—the molecules used to damage and kill their targets. Producing these proteins requires considerable energy.
That energy is generated by the mitochondria, cellular structures responsible for converting nutrients into adenosine triphosphate, or ATP. ATP is the primary molecule cells use to store and transfer energy.
According to the researchers, MEK helps determine how aggressively T cells produce cancer-killing proteins. When MEK signaling becomes excessively active, the demand for energy can become unsustainable and eventually push the cells toward terminal exhaustion.
“We realized T cell exhaustion isn’t simply a loss of function—it reflects an imbalance between what these cells are being asked to do and the energy they have available,” explained Tanmana Mitra, PhD, the study’s first author and a member of the Vardhana laboratory.
Exhausted T Cells May Be Working Too Hard
One of the study’s most unexpected findings was that exhausted T cells were not metabolically inactive. Instead, they remained highly active and were using substantial amounts of energy to produce proteins.
When the researchers treated the cells with MEK inhibitors, the T cells used less energy while showing greater proliferation.
This observation changed how the investigators viewed exhaustion. Rather than resulting only from insufficient energy production, the process may also be driven by excessive energy demand.
By limiting MEK signaling, researchers were able to reduce the pressure on T cells to continuously produce high levels of cytotoxic proteins. This allowed some cells to remain active and self-renewing for longer periods.
The approach can be compared with reducing speed during a long journey. Maintaining maximum intensity may provide a powerful start, but conserving energy may allow the response to continue over a much greater distance.
T-Cell Exhaustion Is Also a Survival Strategy
The findings also reinforce a more nuanced understanding of exhaustion.
Previous work by Memorial Sloan Kettering immunologist Andrea Schietinger, PhD, showed that T cells may enter an exhausted state partly to protect themselves. By reducing their activity, the cells avoid becoming overstimulated and dying.
Exhaustion, therefore, is not necessarily a simple failure of the immune system. It may represent a biological “safe mode” that allows T cells to survive under prolonged pressure.
This creates an important therapeutic dilemma.
MEK signaling supports strong production of cancer-killing proteins, but sustained MEK activity can also contribute to cellular burnout. Blocking MEK may preserve T cells, but it can simultaneously reduce the immediate intensity of their attack.
The clinical question is whether a powerful response that ends quickly is preferable to a more controlled response that can be maintained for longer. The answer may depend on the characteristics of each patient’s cancer.
Who Could Benefit Most From MEK Inhibition?
Dr. Vardhana emphasized that MEK inhibition may not be necessary for every patient receiving immunotherapy.
Patients with relatively small tumors and large numbers of tumor-reactive immune cells may already have enough immune activity to control the disease quickly. These tumors may also carry many mutations, making them easier for the immune system to recognize.
In such cases, preserving T-cell energy may be less important because the immune response may already be close to completing its task. Traditional immunotherapy without MEK inhibition may therefore remain the more appropriate approach.
The situation may be different for patients with larger tumors or fewer immune cells capable of attacking the cancer.
For these patients, a short but intense immune response may not be sufficient. Slowing the rate of T-cell exhaustion could allow immune cells to persist long enough to continue confronting a larger tumor burden or compensate for a smaller immune-cell population.
The researchers suggest that this group—patients who are less likely to respond strongly to conventional immunotherapy—may ultimately derive the greatest value from a MEK-based strategy.
Potential Applications Across Immunotherapy
If confirmed in clinical studies, carefully timed MEK inhibition could have implications across several immunotherapy approaches.
Checkpoint Inhibitors
MEK inhibition has already been used in melanoma alongside checkpoint inhibitors and BRAF-targeted therapy. The new findings offer additional biological insight into how MEK modulation might influence the durability of an immune response.
CAR T-Cell Therapy
Limited T-cell persistence remains an important challenge in chimeric antigen receptor T-cell therapy. By helping engineered T cells conserve energy and survive longer, MEK inhibition could potentially improve the durability of CAR T-cell responses.
Tumor-Infiltrating Lymphocyte Therapy
Tumor-infiltrating lymphocyte therapy uses immune cells that have already entered and attacked a patient’s tumor. MEK inhibition before or after treatment may help selected tumor-fighting lymphocytes remain functional for longer.
Bispecific Antibodies
Bispecific antibodies are laboratory-produced proteins designed to bind two targets simultaneously. Although they can strongly activate T cells, this intense stimulation may also contribute to exhaustion. Modulating MEK signaling could potentially help balance immune activation with cellular persistence.
A Strategy That Will Require Careful Timing
The study does not suggest that MEK signaling should simply be switched off in every patient. MEK is involved in both the strength and sustainability of the immune response, making it a complex therapeutic target.
The challenge will be determining when to allow T cells to operate at maximum intensity and when to encourage them to conserve energy.
Patient selection, tumor burden, the number of tumor-reactive immune cells, and the type of immunotherapy being used may all influence whether MEK inhibition is appropriate.
The findings remain preclinical and will require evaluation in human studies. However, the availability of FDA-approved MEK inhibitors could make clinical testing more feasible.
“This study shows the importance of understanding core principles of T cell biology—what sets the balance between conservation of energy and strong, cancer-fighting activity,” Dr. Vardhana said. “Once we know the answer to that, the therapeutic possibilities really start to fan out.”
Study Details
The study, titled “MEK-Dependent Bioenergetic Demand Drives Terminal CD8+ T Cell Exhaustion,” was published in Immunity.
Additional authors included Jahan Rahman, Madeline Hwee, Yan-Ting Chen, Ruben Jose Jesus Faustino Ramos, Hui Liu, Travis Hartman, Justin Cross, Miguel de Jesus, Morgan Huse, Valerie Longo, and Pat Zanzonico.
The research was supported by an NCI K08 Career Development Award, a Burroughs Wellcome Fund Career Award for Medical Scientists, a V Foundation Scholar Award, the Josie Robertson Investigators Program, a Cancer Center Support Grant, and the Dorris J. Hutchison Pre-doctoral Fellowship at Memorial Sloan Kettering.
Dr. Vardhana has provided consulting services for Generate:Biomedicines and has received research funding from Bristol Myers Squibb unrelated to this work.
Written by Nare Hovhannisyan, MD
You can read more in-depth oncology stories on OncoDaily